Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20471258rdf:typepubmed:Citationlld:pubmed
pubmed-article:20471258lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:20471258lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:20471258lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:20471258lifeskim:mentionsumls-concept:C0682756lld:lifeskim
pubmed-article:20471258lifeskim:mentionsumls-concept:C0205430lld:lifeskim
pubmed-article:20471258lifeskim:mentionsumls-concept:C0028822lld:lifeskim
pubmed-article:20471258lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:20471258pubmed:issue12lld:pubmed
pubmed-article:20471258pubmed:dateCreated2010-6-4lld:pubmed
pubmed-article:20471258pubmed:abstractTextA series of biaryl amides containing an azabicyclooctane amine headpiece were synthesized and evaluated as mixed arginine vasopressin (AVP) receptor antagonists. Several analogues, including 8g, 12g, 13d, and 13g, were shown to have excellent V(1a)- and good V(2)-receptor binding affinities. Compound 13d was further profiled for drug-like properties and for an in vitro comparison with conivaptan, the program's mixed V(1a)/V(2)-receptor antagonist standard.lld:pubmed
pubmed-article:20471258pubmed:languageenglld:pubmed
pubmed-article:20471258pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20471258pubmed:citationSubsetIMlld:pubmed
pubmed-article:20471258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20471258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20471258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20471258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20471258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20471258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20471258pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20471258pubmed:statusMEDLINElld:pubmed
pubmed-article:20471258pubmed:monthJunlld:pubmed
pubmed-article:20471258pubmed:issn1464-3405lld:pubmed
pubmed-article:20471258pubmed:authorpubmed-author:NogleLisa MLMlld:pubmed
pubmed-article:20471258pubmed:authorpubmed-author:CrandallDavid...lld:pubmed
pubmed-article:20471258pubmed:authorpubmed-author:MooreWilliam...lld:pubmed
pubmed-article:20471258pubmed:authorpubmed-author:AntrilliThoma...lld:pubmed
pubmed-article:20471258pubmed:authorpubmed-author:CrombieAimee...lld:pubmed
pubmed-article:20471258pubmed:authorpubmed-author:HeYananYlld:pubmed
pubmed-article:20471258pubmed:authorpubmed-author:FailliAmedeo...lld:pubmed
pubmed-article:20471258pubmed:authorpubmed-author:TrybulskiEuge...lld:pubmed
pubmed-article:20471258pubmed:authorpubmed-author:KernJeffrey...lld:pubmed
pubmed-article:20471258pubmed:authorpubmed-author:CampbellBrand...lld:pubmed
pubmed-article:20471258pubmed:copyrightInfoCopyright 2010 Elsevier Ltd. All rights reserved.lld:pubmed
pubmed-article:20471258pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20471258pubmed:day15lld:pubmed
pubmed-article:20471258pubmed:volume20lld:pubmed
pubmed-article:20471258pubmed:ownerNLMlld:pubmed
pubmed-article:20471258pubmed:authorsCompleteYlld:pubmed
pubmed-article:20471258pubmed:pagination3742-5lld:pubmed
pubmed-article:20471258pubmed:meshHeadingpubmed-meshheading:20471258...lld:pubmed
pubmed-article:20471258pubmed:meshHeadingpubmed-meshheading:20471258...lld:pubmed
pubmed-article:20471258pubmed:meshHeadingpubmed-meshheading:20471258...lld:pubmed
pubmed-article:20471258pubmed:meshHeadingpubmed-meshheading:20471258...lld:pubmed
pubmed-article:20471258pubmed:meshHeadingpubmed-meshheading:20471258...lld:pubmed
pubmed-article:20471258pubmed:meshHeadingpubmed-meshheading:20471258...lld:pubmed
pubmed-article:20471258pubmed:meshHeadingpubmed-meshheading:20471258...lld:pubmed
pubmed-article:20471258pubmed:meshHeadingpubmed-meshheading:20471258...lld:pubmed
pubmed-article:20471258pubmed:meshHeadingpubmed-meshheading:20471258...lld:pubmed
pubmed-article:20471258pubmed:meshHeadingpubmed-meshheading:20471258...lld:pubmed
pubmed-article:20471258pubmed:year2010lld:pubmed
pubmed-article:20471258pubmed:articleTitleSynthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists.lld:pubmed
pubmed-article:20471258pubmed:affiliationChemical Sciences, Pfizer Global Research and Development, Collegeville, PA 19335, USA. aimeecrombie@hotmail.comlld:pubmed
pubmed-article:20471258pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:20471258lld:chembl